Literature DB >> 24859386

Upregulation of hypoxia-inducible factors and autophagy in von Hippel-Lindau-associated retinal hemangioblastoma.

Yujuan Wang1, Mones S Abu-Asab, Defen Shen, Zhengping Zhuang, Emily Y Chew, Chi-Chao Chan.   

Abstract

PURPOSE: To describe pathological and molecular changes of three patients with clinically severe von Hippel-Lindau (VHL)-associated retinal hemangioblastoma (RH) with rapid progression.
METHODS: Medical records, ocular histopathology, and transmission electron microscopy from three cases of VHL-associated RHs at the National Eye Institute were retrospectively reviewed. One eye of each patient was enucleated. Hypoxia-inducible factor (HIF) 1α and HIF2α expressions were identified by quantitative reverse transcription polymerase chain reaction (qRT-PCR) and immunohistochemistry.
RESULTS: All three cases had rapidly growing RHs that were resistant to multiple conventional therapies and two (patients 1 and 2) were also resistant to multiple intravitreal anti-vascular endothelial growth factor (VEGF) treatments. Macroscopically, all the enucleated eyes had multiple RHs, serous retinal detachment, severe retinal disorganization and focal hemorrhages. Histopathology showed typical RHs composed of vacuolated foamy VHL cells and capillary networks. Retinal gliosis and hemorrhages were also presented. Additionally, T lymphocytes and macrophages infiltrated in the tumors of two patients resistant to anti-VEGF therapy. Immunohistochemistry, and qRT-PCR found upregulation of HIF1α in the retinal lesions of all eyes. Importantly, upregulation of HIF2α was exclusively detected in the two cases with inflammatory infiltration and resistance to anti-VEGF therapy. Ultrastructural images showed autophagy, lipid droplets, glycogen aggregations, and cytoplasmic degeneration in many VHL cells.
CONCLUSIONS: Based on the histopathological and molecular pathological findings, autophagy, inflammation, and/or upregulation of HIF2α could potentially contribute to the aggressive course of RHs, resulting in the resistance to multiple anti-VEGF and radiation therapies in these patients.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24859386      PMCID: PMC8329596          DOI: 10.1007/s00417-014-2660-0

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  40 in total

1.  The transcription factor EPAS-1/hypoxia-inducible factor 2alpha plays an important role in vascular remodeling.

Authors:  J Peng; L Zhang; L Drysdale; G H Fong
Journal:  Proc Natl Acad Sci U S A       Date:  2000-07-18       Impact factor: 11.205

2.  VHL gene deletion and enhanced VEGF gene expression detected in the stromal cells of retinal angioma.

Authors:  C C Chan; A O Vortmeyer; E Y Chew; W R Green; D M Matteson; D F Shen; W M Linehan; I A Lubensky; Z Zhuang
Journal:  Arch Ophthalmol       Date:  1999-05

3.  Von Hippel-Lindau gene deletion and expression of hypoxia-inducible factor and ubiquitin in optic nerve hemangioma.

Authors:  Chi-Chao Chan; Youn-Soo Lee; Zhengping Zhuang; Joseph Hackett; Emily Y Chew
Journal:  Trans Am Ophthalmol Soc       Date:  2004

4.  Molecular pathology and CXCR4 expression in surgically excised retinal hemangioblastomas associated with von Hippel-Lindau disease.

Authors:  Xiaoling Liang; Defen Shen; Yongsheng Huang; Chunyue Yin; Christine M Bojanowski; Zhengping Zhuang; Chi-Chao Chan
Journal:  Ophthalmology       Date:  2006-10-27       Impact factor: 12.079

5.  Molecular pathology of primary intraocular lymphoma.

Authors:  Chi-Chao Chan
Journal:  Trans Am Ophthalmol Soc       Date:  2003

6.  Von Hippel-Lindau disease: a genetic study.

Authors:  E R Maher; L Iselius; J R Yates; M Littler; C Benjamin; R Harris; J Sampson; A Williams; M A Ferguson-Smith; N Morton
Journal:  J Med Genet       Date:  1991-07       Impact factor: 6.318

Review 7.  The von Hippel-Lindau tumour suppressor protein: O2 sensing and cancer.

Authors:  William G Kaelin
Journal:  Nat Rev Cancer       Date:  2008-10-16       Impact factor: 60.716

Review 8.  von Hippel-Lindau disease.

Authors:  Russell R Lonser; Gladys M Glenn; McClellan Walther; Emily Y Chew; Steven K Libutti; W Marston Linehan; Edward H Oldfield
Journal:  Lancet       Date:  2003-06-14       Impact factor: 79.321

9.  HIF-1alpha and HIF-2alpha have divergent roles in colon cancer.

Authors:  Takaaki Imamura; Hirotoshi Kikuchi; Maria-Teresa Herraiz; Do-Youn Park; Yusuke Mizukami; Mari Mino-Kenduson; Maureen P Lynch; Bo R Rueda; Yair Benita; Ramnik J Xavier; Daniel C Chung
Journal:  Int J Cancer       Date:  2009-02-15       Impact factor: 7.396

10.  The contribution of VHL substrate binding and HIF1-alpha to the phenotype of VHL loss in renal cell carcinoma.

Authors:  Jodi K Maranchie; James R Vasselli; Joseph Riss; Juan S Bonifacino; W Marston Linehan; Richard D Klausner
Journal:  Cancer Cell       Date:  2002-04       Impact factor: 31.743

View more
  9 in total

1.  Rb1/Rbl1/Vhl loss induces mouse subretinal angiomatous proliferation and hemangioblastoma.

Authors:  Ran Wei; Xiang Ren; Hongyu Kong; Zhongping Lv; Yongjiang Chen; Yunjing Tang; Yujiao Wang; Lirong Xiao; Tao Yu; Sabiha Hacibekiroglu; Chen Liang; Andras Nagy; Rod Bremner; Danian Chen
Journal:  JCI Insight       Date:  2019-11-14

Review 2.  Von Hippel-Lindau disease.

Authors:  Prashant Chittiboina; Russell R Lonser
Journal:  Handb Clin Neurol       Date:  2015

3.  Pathology characteristics of ocular von Hippel-Lindau disease with neovascularization of the iris and cornea: a case report.

Authors:  Shida Chen; Emily Y Chew; Chi-Chao Chan
Journal:  J Med Case Rep       Date:  2015-03-25

4.  Von Hippel-Lindau Disease: The Importance of Retinal Hemangioblastomas in Diagnosis.

Authors:  Sevinç Şahin Atik; Aslı Ece Solmaz; Zafer Öztaş; Emine Deniz Eğrilmez; Şeyda Uğurlu; Tahir Atik; Filiz Afrashi
Journal:  Turk J Ophthalmol       Date:  2017-06-01

5.  Repurposing propranolol as a drug for the treatment of retinal haemangioblastomas in von Hippel-Lindau disease.

Authors:  Virginia Albiñana; Rosa María Jiménez Escribano; Isabel Soler; Luis Rodríguez Padial; Lucia Recio-Poveda; Karina Villar Gómez de Las Heras; Luisa María Botella
Journal:  Orphanet J Rare Dis       Date:  2017-06-29       Impact factor: 4.123

6.  3-D OCT angiographic evidence of Anti-VEGF therapeutic effects on retinal capillary hemangioma.

Authors:  Oscar Otero-Marquez; Toco Yp Chui; Alexander Pinhas; Maria V Castanos Toral; Davis B Zhou; Justin Migacz; Richard B Rosen
Journal:  Am J Ophthalmol Case Rep       Date:  2022-02-07

7.  Retinal Hemangioblastoma with Extraocular Extension: Report of Three Cases.

Authors:  Namita Kumari; Sima Das; Anirban Bhaduri; Arpan Gandhi
Journal:  Ocul Oncol Pathol       Date:  2021-01-07

Review 8.  Ocular Manifestations of von Hippel-Lindau Disease.

Authors:  Misty D Ruppert; Meredith Gavin; Kelly T Mitchell; Alan N Peiris
Journal:  Cureus       Date:  2019-08-04

9.  Insights into retinal hemangioblastoma using ultra widefield imaging.

Authors:  Pradeep Kumar; Raghav Ravani; Sahil Agarwal; Suman Dhanda; Vinod Kumar
Journal:  Indian J Ophthalmol       Date:  2019-12       Impact factor: 1.848

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.